The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Progression-free Survival
Timeframe: 3 months after MR-Linac treatment
Progression-free Survival
Timeframe: 6 months after MR-Linac treatment
Progression-free Survival
Timeframe: 24 months after MR-Linac treatment
Survival
Timeframe: 3 months after MR-Linac treatment
Survival
Timeframe: 6 months after MR-Linac treatment
Survival
Timeframe: 24 months after MR-Linac treatment
Disease-free Survival
Timeframe: 3 months after MR-Linac treatment
Disease-free Survival
Timeframe: 6 months after MR-Linac treatment
Disease-free Survival
Timeframe: 24 months after MR-Linac treatment
Patient reported Health related quality of life (HRQoL).
Timeframe: 3 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 6 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 12 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 24 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 3 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 6 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 12 months after treatment.
Patient reported Health related quality of life (HRQoL).
Timeframe: 24 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 3 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 6 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 12 months after treatment.
Patient reported tumor specific quality of life (QoL).
Timeframe: 24 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 3 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 6 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 12 months after treatment.
Acute toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 24 months after treatment.
Clinical tumor response.
Timeframe: 2 year follow up.
Pathological tumor response.
Timeframe: 2 year follow up.
Toxicity in common toxicity criteria for adverse events (CTCAE).
Timeframe: 2 years